Temisis

Executive Summary

Temisis Therapeutics is a preclinical French biotechnology company founded in 2017, dedicated to developing novel small-molecule drugs for inflammatory diseases. Its lead program, TEM-1657, targets psoriasis and has demonstrated significant efficacy and a best-in-class safety profile in preclinical studies. The company is exploring both topical and oral formulations to address different patient needs. Despite its promising preclinical data, Temisis remains in the preclinical stage with no disclosed funding rounds or clinical trial initiations, which may raise concerns about its ability to advance without external partnerships or financing. Given the competitive landscape for psoriasis treatments, Temisis must accelerate its path to the clinic to attract investors or licensing partners. The company's long preclinical timeline (nine years since founding) suggests it may have faced challenges in securing capital or navigating regulatory requirements. However, if TEM-1657 proves successful in Phase 1 trials, it could offer a differentiated profile in the inflammatory disease space. The upcoming catalysts include regulatory filings, funding rounds, and potential partnerships, which will be critical for its progression.

Upcoming Catalysts (preview)

• Q3 2026IND/CTA Filing for TEM-165740% success
• Q4 2026Series A Financing Round50% success
• Q1 2027Licensing Partnership for Psoriasis Program30% success